Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Mature
Primary summary from verified readiness
- Confidence
- 65% · fresh
- Computed at
- 2026-08-20T10:56:20.278175+00:00
- Claimed
- 100
- Reported
- 99
- Verified
- 93
- Gap
- +7
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Adopt with guardrails
- Why
- Traditional (non-accelerated) FDA approval plus expanding multi-country reimbursement (US, Japan, China, EU, Canada, South Korea, Mexico) establishes lecanemab as the validated commercial and clinical benchmark for the anti-amyloid disease-modifying class that donanemab/Kisunla is measured against, but the boxed ARIA warning, an initial EU regulatory rejection, and uneven international reimbursement mean the class still carries real, disclosed limitations.
- Next
- Track EU/China reimbursement rollout, real-world ARIA safety registry data, and subcutaneous (IQLIK) adoption curve before any platform content positions anti-amyloid therapy as low-risk or universally accessible
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 1
- Tier 3
- 5
- Supports
- 3
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-08-20
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-08-20 Reading moved from mature to mature.